Bid document

SUBJECT*

Development/Production - Kidney GEC-Specific AAV Vector

GENERAL INFORMATION

CONTRACTING OFFICE’S ZIP CODE*

15215-1802

SOLICITATION NUMBER*

36C24E27Q0009

RESPONSE DATE/TIME/ZONE

11-04-2026 12:00 PM EASTERN TIME, NEW YORK, USA

ARCHIVE

5 DAYS AFTER THE RESPONSE DATE

RECOVERY ACT FUNDS

N

SET-ASIDE

PRODUCT SERVICE CODE*

AJ12

NAICS CODE*

541714

CONTRACTING OFFICE ADDRESS

Veterans Health Administration
Regional Procurement Office East
Building 32 Suite 1A1111
1010 Delafield Road
Pittsburgh PA 15215-1802

POINT OF CONTACT*

Contract Specialist
Mae McGarry
[email protected]
814-860-2606

PLACE OF PERFORMANCE

ADDRESS

Department of Veteran Affairs

Harry S Truman Memorial Veterans Hospital

Research Service

800 Hospital Drive

Columbia MO

POSTAL CODE

65201

COUNTRY

USA

ADDITIONAL INFORMATION

AGENCY’S URL

URL DESCRIPTION

AGENCY CONTACT’S EMAIL ADDRESS

EMAIL DESCRIPTION

DESCRIPTION

The following is a Sources Sought/Request for Information notice. This posted notice is not a Pre- Solicitation or Solicitation document. The government is not currently soliciting bids, quotes or proposals at this time; however, reserves the right to do so at a later date. The Harry S Truman Memorial Veterans Hospital, Columbia, MO 65201 has a brand name only requirement for Development/Production- Kidney GEC- Specific AAV Vector. Statement of Work (SOW)

For GECTargeted AdenoAssociated Virus Vector Development Contract Description: Development and production of a kidney glomerular endothelial cell–specific AAV vector for VA preclinical research.

1.0 Scope of Work:

1.1 This requirement is a VA ORD Merit funded project (#1I21RD001234-01) to develop a kidney glomerular endothelial cell–specific viral vector.

1.2 The goal of the project is to build a homing peptideenabled vector platform capable of targeting the glomerular endothelium to treat kidney injury and disease and to enhance traditional pharmacologic approaches.

1.3 The work will modify the capsid of an endothelialspecific, nonimmunogenic viral vector by incorporating a peptide that specifically targets kidney glomerular endothelial cells (GEC), with the objective of increasing specificity, reducing offtarget transduction, and overcoming known limitations in vector targeting to the kidney.

2.0 Background:

2.1 This requirement in response to RD-01-PILT: ISRM Pilot Project Award I21 was selected for funding by ORD; Merit funded project (1I21RD001234-01).

2.2 Despite aggressive management of blood pressure and glycemic control, the prevalence of kidney disease continues to rise, highlighting the need for adjunctive, individualized approaches that advance precision medicine. The project aims to build a homing peptideenabled vector platform targeting the glomerular endothelium to treat kidney injury and disease and to augment current therapeutic strategies.